Patient Access

Brand-Name Drug Denials Surge, Straining Patient Access Pathways

A new study finds nearly one-third of prescriptions were rejected on the first fill attempt, with brand-name and weight-loss drugs seeing the steepest denial rates. For specialty pharma, first-fill rejections are more than an administrative inconvenience—they are a leading cause of therapy abandonment and delayed time-to-treatment. As payers tighten utilization management, manufacturers and hub programs must anticipate friction earlier in the patient journey. Stakeholders should watch how prior authorization automation and benefits verification evolve to counter rising rejection volumes.

RxWare Perspective

First-fill denials are where access programs win or lose patients; proactive benefits investigation and real-time PA support convert rejections into fills before abandonment sets in. The manufacturers who instrument this moment will protect both patient outcomes and therapy persistence.

Pharma Trends

4 stories

Market

AstraZeneca–Bristol Myers Merger Talks Rattle Wall Street

Reports of merger discussions between AstraZeneca and Bristol Myers Squibb would create the world's largest drugmaker by revenue, but investors reacted coolly, wiping tens of billions from AstraZeneca's market value. Analysts say the deal faces long odds.

RxWare View: Portfolio consolidation from mega-mergers can disrupt continuity of hub and access services, so manufacturers should build access infrastructure resilient to organizational change.

BioPharma Dive · 1d ago

Pipeline

Regeneron Enters Radiopharma via $2.1B Telix Partnership

Regeneron tapped Australian biotech Telix in a multi-pronged $2.1 billion agreement to enter the radiopharmaceutical market. The deal underscores growing large-pharma appetite for targeted radioligand therapies.

RxWare View: Radiopharmaceuticals demand access models built around time-sensitive logistics and site coordination, not just traditional benefits verification.

PharmaVoice · 3d ago

Pipeline

Lilly Bets Up to $3.8B on Psychedelic-Derived Drug Program

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with contingent milestones pushing the total to $3.8 billion. The deal makes Lilly the first large pharma to build a full development program around a Schedule I psychedelic compound.

RxWare View: Psychedelic therapies will require access programs that integrate controlled-substance handling, site certification, and supervised administration from day one.

Drug Discovery Trends · 2d ago

Market

Specialty Pharma's Infrastructure Gap Runs Deeper Than IT

A new analysis argues that technology enabling the specialty patient journey has become an IT problem—but IT alone cannot solve it. The fix requires domain expertise embedded alongside systems, not delegated to them.

RxWare View: Durable specialty access infrastructure combines technology with embedded access expertise—automation without domain fluency simply scales friction.

PharmaVoice · 5d ago

Regulatory Watch

2 updates

Policy

Revised 340B Rebate Plan Reshapes Discount Program Debate

A revised 340B rebate model is drawing renewed attention as regulators and manufacturers grapple with how discounts are administered. The proposal could shift the mechanics of one of specialty pharma's most contested programs.

RxWare View: Any shift to a 340B rebate model will require access programs to track eligibility and reconciliation with far greater precision across covered entities.

STAT News · 1d ago

Policy

New Tariff Proposal Aims to Reshore Generic Drug Production

The administration unveiled a revised tariff plan giving pharma more time to transition global supply chains and reshore generic manufacturing. Questions remain over whether the incentives will meaningfully shift production.

RxWare View: Supply chain policy shifts introduce availability risk that access programs must monitor, even for therapies outside the generic space.

PharmaVoice · 1d ago

RxWare Perspective

The First-Fill Access Moment

The first fill attempt is emerging as the decisive point in the specialty patient journey. With denial rates approaching one-third on initial submission, access programs that resolve rejections in real time—rather than after abandonment—will define therapy persistence in 2026 and beyond.

New Modalities, New Access Models

Radiopharmaceuticals, psychedelic therapies, and cell-based treatments are outpacing the access infrastructure built for traditional specialty drugs. Manufacturers investing in these categories must design delivery models around site certification, time-sensitive logistics, and supervised administration from the earliest commercial planning stages.

Expertise Over Automation

The specialty access challenge is increasingly framed as a technology problem, but automation without domain fluency simply scales existing friction. The most resilient programs pair purpose-built systems with embedded access expertise, treating infrastructure as a hybrid of software and specialized knowledge.

Upcoming in Specialty Pharma

OCT 19

Conference

AMCP Nexus 2026

October 19, 2026 · Las Vegas, NV

Managed care and specialty pharmacy leaders convene on formulary, utilization management, and access policy shaping specialty drug coverage.

Visit website ↗

OCT 25

Conference

AAPS PharmSci 360

October 25, 2026 · New Orleans, LA

Pharmaceutical science and USP sessions relevant to specialty product development, formulation, and quality standards.

Visit website ↗

APR 26

Summit

Asembia AXS Specialty Pharmacy Summit

April 26, 2027 · Las Vegas, NV

The premier gathering for specialty pharmacy stakeholders covering patient access, hub services, and channel strategy.

Visit website ↗

What is MCP?